Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hidetoshi Hayashi

Showing results (1-10 of 333) with videos related to

Pageof 34
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 19, 2021
[Handling of Japanese Subgroup Data in Global Clinical Trials and Its Clinical Significance-In Terms of Systemic Therapies for Advanced Lung Cancer]Takashi Kurosaki, Hidetoshi Hayashi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 16, 2017
[Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation]Hidetoshi Hayashi, Tetsuya Mitsudomi
International Journal of Clinical Oncology|September 25, 2019
Combination therapy with PD-1 or PD-L1 inhibitors for cancerHidetoshi Hayashi, Kazuhiko Nakagawa
Respiratory Investigation|May 6, 2025
Current treatment landscape for patients with non-small cell lung cancer with common EGFR mutationsMasayuki Miyata, Hidetoshi Hayashi
Med (New York, N.Y.)|April 12, 2026
Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinomaHiroaki Kanemura, Hidetoshi Hayashi
Current Oncology (Toronto, Ont.)|July 25, 2022
Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung CancerSteven Olsen, Jiemin Liao, Hidetoshi Hayashi
Clinical Medicine Insights. Oncology|June 23, 2011
Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancerHidetoshi Hayashi, Takayasu Kurata, Kazuhiko Nakagawa
Investigational New Drugs|September 25, 2010
Perirenal hematoma associated with bevacizumab treatmentHidetoshi Hayashi, Isamu Okamoto, Kazuhiko Nakagawa
Biological & Pharmaceutical Bulletin|April 3, 2015
Pseudokinase tribbles 1 (TRB1) negatively regulates tumor-suppressor activity of p53 through p53 deacetylationChiharu Miyajima, Yasumichi Inoue, Hidetoshi Hayashi
Chemical Communications (Cambridge, England)|August 13, 2002
2,2-Difluoro-1,3-dimethylimidazolidine (DFI). A new fluorinating agentHidetoshi Hayashi, Hiroshi Sonoda, Kouki Fukumura, et al.
Pageof 34

Showing results (1-10 of 333) with videos related to

Sort By:
Pageof 34
Gan to Kagaku Ryoho. Cancer & Chemotherapy|November 19, 2021
[Handling of Japanese Subgroup Data in Global Clinical Trials and Its Clinical Significance-In Terms of Systemic Therapies for Advanced Lung Cancer]Takashi Kurosaki, Hidetoshi Hayashi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 16, 2017
[Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation]Hidetoshi Hayashi, Tetsuya Mitsudomi
International Journal of Clinical Oncology|September 25, 2019
Combination therapy with PD-1 or PD-L1 inhibitors for cancerHidetoshi Hayashi, Kazuhiko Nakagawa
Respiratory Investigation|May 6, 2025
Current treatment landscape for patients with non-small cell lung cancer with common EGFR mutationsMasayuki Miyata, Hidetoshi Hayashi
Med (New York, N.Y.)|April 12, 2026
Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinomaHiroaki Kanemura, Hidetoshi Hayashi
Current Oncology (Toronto, Ont.)|July 25, 2022
Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung CancerSteven Olsen, Jiemin Liao, Hidetoshi Hayashi
Clinical Medicine Insights. Oncology|June 23, 2011
Gemcitabine: efficacy in the treatment of advanced stage nonsquamous non-small cell lung cancerHidetoshi Hayashi, Takayasu Kurata, Kazuhiko Nakagawa
Investigational New Drugs|September 25, 2010
Perirenal hematoma associated with bevacizumab treatmentHidetoshi Hayashi, Isamu Okamoto, Kazuhiko Nakagawa
Biological & Pharmaceutical Bulletin|April 3, 2015
Pseudokinase tribbles 1 (TRB1) negatively regulates tumor-suppressor activity of p53 through p53 deacetylationChiharu Miyajima, Yasumichi Inoue, Hidetoshi Hayashi
Chemical Communications (Cambridge, England)|August 13, 2002
2,2-Difluoro-1,3-dimethylimidazolidine (DFI). A new fluorinating agentHidetoshi Hayashi, Hiroshi Sonoda, Kouki Fukumura, et al.
Pageof 34